Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1700776

registered interest
date	15/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Drugs: Prices
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government when they will publish a timeline for the implementation of the proposed changes to Drug Tariff Part IX; provide the definition of "quality" that will be used as part of the enhanced assessment process included in those proposed changes; and publish in full the responses received to that consultation.
tabling member printed	Lord Hunt of Kings Heath
uin	HL3748
answer	answer is ministerial correction date of answer 22/04/2024 answer text <p>The consultation response on the proposed amendments to Part IX is expected to be released in May 2024, which will outline the Government’s response. Any amendments that are taken forward will happen gradually, with review points, and engagement with stakeholders, including industry, patient representatives, clinicians, and National Health Service organisations. The Department will share a timeline of the proposed changes taken forward in due course.</p><p>The Department believes that it is currently difficult to identify which devices are broadly comparable, and whether more expensive devices provide added value. The proposed amendments that were consulted on intend to increase meaningful choice, not to decrease choice for clinicians and patients. Comparison between products can increase awareness of different brands amongst prescribers, which can also support small and medium sized businesses in entering the market.</p><p>The Department is aware that there are some very good devices in use, relied upon by clinicians and patients. Part IX will remain a list of devices available to be prescribed in the community via the FP10 prescription route.</p> answering member printed Lord Markham grouped question UIN HL3749 question first answered 22/04/2024 15:14:34 answering member 4948 label Biography information for Lord Markham
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

1700777

registered interest
date	15/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Incontinence: Drugs
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what plans they have to consult patients, clinicians and manufacturers on the categorisation of products available on Part IX of the Drug Tariff as proposed in the recent consultation paper; and what assessment they have made of the impact of the proposed changes to Drug Tariff Part IX on (1) patients with continence care needs, (2) continence care services, (3) the range of devices available to clinicians and patients, and (4) new product development and innovation in medical devices in the continence sector.
tabling member printed	Lord Hunt of Kings Heath
uin	HL3749
answer	answer is ministerial correction date of answer 22/04/2024 answer text <p>The consultation response on the proposed amendments to Part IX is expected to be released in May 2024, which will outline the Government’s response. Any amendments that are taken forward will happen gradually, with review points, and engagement with stakeholders, including industry, patient representatives, clinicians, and National Health Service organisations. The Department will share a timeline of the proposed changes taken forward in due course.</p><p>The Department believes that it is currently difficult to identify which devices are broadly comparable, and whether more expensive devices provide added value. The proposed amendments that were consulted on intend to increase meaningful choice, not to decrease choice for clinicians and patients. Comparison between products can increase awareness of different brands amongst prescribers, which can also support small and medium sized businesses in entering the market.</p><p>The Department is aware that there are some very good devices in use, relied upon by clinicians and patients. Part IX will remain a list of devices available to be prescribed in the community via the FP10 prescription route.</p> answering member printed Lord Markham grouped question UIN HL3748 question first answered 22/04/2024 15:14:34 answering member 4948 label Biography information for Lord Markham
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

1700778

registered interest
date	15/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Health Services: Legal Representation
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what was the annual spend by the health service on legal representation at inquests in the previous five years for which information is available.
tabling member printed	Lord Hunt of Kings Heath
uin	HL3750
answer	answer is ministerial correction date of answer 14/05/2024 answer text <p>NHS Resolution manages clinical negligence and other claims against the National Health Service in England. The following table shows the amounts paid in accordance with the rules of the Clinical Negligence Scheme for Trusts (CNST), to support trusts at inquests and for associated costs to investigate entitlement to compensation, in the last five years:</p><table><tbody><tr><td><p>Payment Raised Year</p></td><td><p>Amount</p></td></tr><tr><td><p>2018/19</p></td><td><p>£2,968,153</p></td></tr><tr><td><p>2019/20</p></td><td><p>£2,223,095</p></td></tr><tr><td><p>2020/21</p></td><td><p>£1,614,820</p></td></tr><tr><td><p>2021/22</p></td><td><p>£1,545,135</p></td></tr><tr><td><p>2022/23</p></td><td><p>£1,623,211</p></td></tr><tr><td><p>Total</p></td><td><p>£9,974,414</p></td></tr></tbody></table><p>Source: NHS Resolution</p><p>The CNST handles all clinical negligence claims against member NHS bodies where the incident in question took place on or after 1 April 1995, or when the body joined the scheme if that is later. NHS Resolution is not involved in any arrangements that an individual trust might make outside of the scheme.</p><p>Information on the total spend by NHS trusts regarding coroner’s inquests is not collated or held centrally.</p> answering member printed Lord Markham question first answered 14/05/2024 11:49:03 answering member 4948 label Biography information for Lord Markham
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

1699226

registered interest
date	26/03/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Health Services: Procurement
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what recent assessment they have made regarding the potential for insourcing to tackle NHS waiting lists.
tabling member printed	Lord Hunt of Kings Heath
uin	HL3616
answer	answer is ministerial correction date of answer 08/04/2024 answer text <p>Independent sector providers have a significant role to play in supporting the National Health Service as trusted partners, to recover elective services. The Elective Recovery Taskforce was launched in 2022 to consider how capacity across the system could be best utilised, including how insourcing could be used to meet the ambitions on long waits. The taskforce concluded its work by publishing an implementation plan in August 2023, which sets out a series of actions that have either been delivered, or will be delivered, over the coming months.</p><p>Local systems are best placed to consider how to utilise insourcing as part of their delivery plans, in a way which works for their areas. To support the system, NHS England produced <em>Guidance for trusts on the use of insourcing</em> and NHS Shared Business Services produced the <em>Insourcing of Clinical Services Framework Agreement</em>.</p> answering member printed Lord Markham grouped question UIN HL3587 HL3617 question first answered 08/04/2024 11:17:10 answering member 4948 label Biography information for Lord Markham
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

1699227

registered interest
date	26/03/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Health Services: Procurement
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what steps they have taken to ensure that NHS trusts are made aware of (1) insourcing arrangements as a route to reducing local waiting lists, and (2) the benefits of insourcing for (a) patients, and (b) NHS trusts.
tabling member printed	Lord Hunt of Kings Heath
uin	HL3617
answer	answer is ministerial correction date of answer 08/04/2024 answer text <p>Independent sector providers have a significant role to play in supporting the National Health Service as trusted partners, to recover elective services. The Elective Recovery Taskforce was launched in 2022 to consider how capacity across the system could be best utilised, including how insourcing could be used to meet the ambitions on long waits. The taskforce concluded its work by publishing an implementation plan in August 2023, which sets out a series of actions that have either been delivered, or will be delivered, over the coming months.</p><p>Local systems are best placed to consider how to utilise insourcing as part of their delivery plans, in a way which works for their areas. To support the system, NHS England produced <em>Guidance for trusts on the use of insourcing</em> and NHS Shared Business Services produced the <em>Insourcing of Clinical Services Framework Agreement</em>.</p> answering member printed Lord Markham grouped question UIN HL3587 HL3616 question first answered 08/04/2024 11:17:10 answering member 4948 label Biography information for Lord Markham
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

1699228

registered interest
date	26/03/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cancer: Research
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government whether they will establish targeted funding to prioritise and drive research investment into pancreatic cancer and the other less survivable cancers.
tabling member printed	Lord Hunt of Kings Heath
uin	HL3618
answer	answer is ministerial correction date of answer 08/04/2024 answer text <p>Research is crucial in the fight against cancer, which is why the Department invests £1 billion per year in health research through the National Institute for Health and Care Research (NIHR). NIHR research expenditure for all cancers was £121 million for 2022/23.</p><p>In terms of establishing targeted funding into pancreatic cancer, the NIHR funds research in response to proposals received from scientists rather than allocating funding to specific disease areas. It is not usual practice to ring-fence funds for particular topics or conditions. Applications are subject to peer review and judged in open competition, with awards made on the basis of the importance of the topic to patients and health and care services, value for money, and scientific quality.</p><p>The Government, through the NIHR, is committed to improving research into pancreatic cancer and cancers with the poorest survival rates by funding high quality, timely research that leads to improved outcomes for patients and the public, and makes the health and social care system more efficient, effective, and safe. Research evidence is vital for improving treatments and outcomes for people, including those with pancreatic cancer and other less survivable cancers.</p><p>In 2023, the Government awarded £2 million to new interdisciplinary research teams tackling hard to treat cancers, via the Medical Research Council, which hosted a two-day cancer sandpit strategic funding opportunity, focused on technological innovation for understanding cancers with the poorest survival rates.</p><p>The NIHR has funded seven research projects for pancreatic cancer for the period 2019 to 2023, with a total committed spend of approximately £3.6 million. The NIHR also supports the delivery of pancreatic cancer research funded by those in the charity and public sectors. For example, since 2019, the NIHR Clinical Research Network has supported over 70 pancreatic cancer-related studies.</p><p>The NIHR continues to encourage and welcome applications for research into any aspect of human health, including pancreatic cancer. All applications are assessed for funding by peer review committees. The level of research spend in a particular area is driven by factors including the quality of the proposals and their scientific potential. All applications for research into pancreatic cancer and other less survivable cancers made through open competition have been funded.</p> answering member printed Lord Markham grouped question UIN HL3619 question first answered 08/04/2024 11:25:36 answering member 4948 label Biography information for Lord Markham
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

1699229

registered interest
date	26/03/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cancer: Research
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government whether they will encourage the National Institute for Health and Care Research to rigorously evaluate existing research efforts and review how they can further prioritise and drive research investment for pancreatic cancer and other less survivable cancers.
tabling member printed	Lord Hunt of Kings Heath
uin	HL3619
answer	answer is ministerial correction date of answer 08/04/2024 answer text <p>Research is crucial in the fight against cancer, which is why the Department invests £1 billion per year in health research through the National Institute for Health and Care Research (NIHR). NIHR research expenditure for all cancers was £121 million for 2022/23.</p><p>In terms of establishing targeted funding into pancreatic cancer, the NIHR funds research in response to proposals received from scientists rather than allocating funding to specific disease areas. It is not usual practice to ring-fence funds for particular topics or conditions. Applications are subject to peer review and judged in open competition, with awards made on the basis of the importance of the topic to patients and health and care services, value for money, and scientific quality.</p><p>The Government, through the NIHR, is committed to improving research into pancreatic cancer and cancers with the poorest survival rates by funding high quality, timely research that leads to improved outcomes for patients and the public, and makes the health and social care system more efficient, effective, and safe. Research evidence is vital for improving treatments and outcomes for people, including those with pancreatic cancer and other less survivable cancers.</p><p>In 2023, the Government awarded £2 million to new interdisciplinary research teams tackling hard to treat cancers, via the Medical Research Council, which hosted a two-day cancer sandpit strategic funding opportunity, focused on technological innovation for understanding cancers with the poorest survival rates.</p><p>The NIHR has funded seven research projects for pancreatic cancer for the period 2019 to 2023, with a total committed spend of approximately £3.6 million. The NIHR also supports the delivery of pancreatic cancer research funded by those in the charity and public sectors. For example, since 2019, the NIHR Clinical Research Network has supported over 70 pancreatic cancer-related studies.</p><p>The NIHR continues to encourage and welcome applications for research into any aspect of human health, including pancreatic cancer. All applications are assessed for funding by peer review committees. The level of research spend in a particular area is driven by factors including the quality of the proposals and their scientific potential. All applications for research into pancreatic cancer and other less survivable cancers made through open competition have been funded.</p> answering member printed Lord Markham grouped question UIN HL3618 question first answered 08/04/2024 11:25:36 answering member 4948 label Biography information for Lord Markham
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

1699230

registered interest
date	26/03/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Health Services
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government when the major conditions strategy will be published.
tabling member printed	Lord Hunt of Kings Heath
uin	HL3620
answer	answer is ministerial correction date of answer 11/04/2024 answer text <p>Our intention is to publish the Major Conditions Strategy in the summer of this year.</p> answering member printed Lord Markham question first answered 11/04/2024 10:53:56 answering member 4948 label Biography information for Lord Markham
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

1699231

registered interest
date	26/03/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS England: Data Protection
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what deficiency in NHS England’s Secure Data Environment was described in paragraph 5.1.10 of the minutes from the 29 February meeting of the Advisory Group for Data, and what steps are being taken to rectify that deficiency.
tabling member printed	Lord Hunt of Kings Heath
uin	HL3621
answer	answer is ministerial correction date of answer 08/04/2024 answer text <p>The point made in the meeting was unrelated to any deficiency within the Secure Data Environment (SDE). The requirement from the Home Office is for specific statistical models and systems to be applied across the dataset requested, which is made up of aggregated data. This specific functionality is available from within the Home Office’s own technical environment, and not from within the SDE. There are no plans at this time to migrate this functionality within the SDE.</p> answering member printed Lord Markham question first answered 08/04/2024 11:26:03 answering member 4948 label Biography information for Lord Markham
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

1698279

registered interest
date	25/03/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Databases
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government further to the Written Answers by Lord Markham on 27 February 2023 (HL5458) and 14 March 2023 (HL5916), whether they will place in the Library of the House a copy of the YAML, R and Python code exportable from NHS England's Federated Data Platform for (1) the Ambulance Dataset Dashboard, and (2) the COVID Monitoring Reporting and Publication Dashboard.
tabling member printed	Lord Hunt of Kings Heath
uin	HL3583
answer	answer is ministerial correction date of answer 05/04/2024 answer text <p>NHS England will from time to time publish examples of code and specifications that are deemed useful to the wider community and industry, including where appropriate, the sharing of code within the NHS GitHub.</p><p> </p><p>To ensure that NHS England is creating a vibrant marketplace for both end users and for industry, it aims to publish the Canonical Data Model structures as well as the metadata, in line with the Tech Code of Practice.</p><p> </p><p>The Federated Data Platform (FDP) Programme is developing a sustainable way to publish examples of specifications and code for specific FDP products. The programme is working through a set of core principles to help determine how they will publish analysis code publicly. This includes making sure that there is appropriate explanatory information surrounding the code, that will help to provide additional context for those viewing the information.</p> answering member printed Lord Markham question first answered 05/04/2024 13:33:02 answering member 4948 label Biography information for Lord Markham
tabling member	2024 label Biography information for Lord Hunt of Kings Heath